Obinutuzumab for untreated advanced follicular lymphoma.
Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.
Published: March 2018
Next review: March 2021
Full guidance available at: https://www.nice.org.uk/guidance/ta513
Showing posts with label lymph. Show all posts
Showing posts with label lymph. Show all posts
Wednesday, 21 March 2018
Thursday, 9 November 2017
Ibrutinib in combination with obinutuzumab for the treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma in elderly – first line
The combination of ibrutinib (oral capsules) and obinutuzumab (intravenous injection) is being developed as a new treatment option for CLL/SLL in elderly patients. Both drugs act in different unique ways to improve the body’s natural defence to fight the cancer cells and their combined effect may significantly reduce symptoms of the disease and increase survival.
From the NIHR Innovation Observatory
From the NIHR Innovation Observatory
Lenalidomide (Revlimid) + rituximab for relapsed/refractory follicular lymphoma and marginal zone lymphoma
The drug combination of lenalidomide (oral capsules) and rituximab (by intravenous injection) has the potential to be an effective treatment for relapsed or refractory follicular and marginal zone lymphoma. The drug combination is being developed for patients that are eligible for rituximab monotherapy or for patients that need an alternative to standard chemotherapy regimens, where rituximab alone would be considered sub-optimal.
From the NIHR Innovation Observatory
From the NIHR Innovation Observatory
Wednesday, 4 October 2017
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults
Tuesday, 19 September 2017
Uniportal VATS lymphadenectomy
criticism of limitations in minimally invasive techniques regarding lymphadenectomy has been shown not to be evidenced. We describe the techniques of mediastinal lymphadenectomies during the uniportal VATS (uniVATS) approach with video attachments.
UHCW Research: Antonio E. Martin-Ucar
Monday, 11 September 2017
Measuring impact of chemotherapy upon AMH and fertility in breast cancer and lymphoma patients relative to normal controls- 5-year multicentre study
Fertility and Sterility , Volume 108 , Issue 3 , e31
Reproductive age women with malignancy have lower AMH than controls even before starting chemotherapy. Our study confirmed strong correlation between pre-chemotherapy AMH and post-chemotherapy AMH (measured at 1 and 5-year) in young women diagnosed with breast cancer.
Low/undetectable serum AMH concentration 12 months after starting chemotherapy does not exclude future pregnancy. There is an unmet need for fertility consultation and preservation in young women diagnosed with cancer.
UHCW Research: T Ghobara
Reproductive age women with malignancy have lower AMH than controls even before starting chemotherapy. Our study confirmed strong correlation between pre-chemotherapy AMH and post-chemotherapy AMH (measured at 1 and 5-year) in young women diagnosed with breast cancer.
Low/undetectable serum AMH concentration 12 months after starting chemotherapy does not exclude future pregnancy. There is an unmet need for fertility consultation and preservation in young women diagnosed with cancer.
UHCW Research: T Ghobara
Thursday, 31 August 2017
Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab [TA472[
New Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for adults with follicular lymphoma that did not respond or progressed after treatment with rituximab.
Obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance is recommended for use within the Cancer Drugs Fund as an option for treating adults with follicular lymphoma that did not respond or progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen, only if the conditions in the managed access agreement for obinutuzumab are followed.
Obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance is recommended for use within the Cancer Drugs Fund as an option for treating adults with follicular lymphoma that did not respond or progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen, only if the conditions in the managed access agreement for obinutuzumab are followed.
Thursday, 24 August 2017
Liposuction for chronic lymphoedema [IPG588]
Liposuction for chronic lymphoedema Current evidence on the safety and efficacy of liposuction for chronic lymphoedema is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit.
Patient selection should only be done by a multidisciplinary team as part of a lymphoedema service.
Thursday, 10 August 2017
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma [TA462]
New NICE Technology Appraisal Guidance on using nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults.
Nivolumab is recommended, within its marketing authorisation, as an option for treating relapsed or refractory classical Hodgkin lymphoma in adults after autologous stem cell transplant and treatment with brentuximab vedotin, when the company provides nivolumab with the discount agreed in the patient access scheme.
Nivolumab is recommended, within its marketing authorisation, as an option for treating relapsed or refractory classical Hodgkin lymphoma in adults after autologous stem cell transplant and treatment with brentuximab vedotin, when the company provides nivolumab with the discount agreed in the patient access scheme.
Monday, 17 July 2017
L-Dex U400 for lymphoedema after breast cancer treatment
New Medtech innovation briefing from NICE on using the L-Dex U400 for lymphoedema after breast cancer treatment.
The innovative aspects are that it uses bioimpedance spectroscopy to measure fluid status, aiming to detect lymphoedema earlier.
The intended place in therapy would be in diagnosing or monitoring lymphoedema related to breast cancer treatment. It could be used as an alternative to current detection or measurement techniques, such as simple tape measurement of limb circumference.
The innovative aspects are that it uses bioimpedance spectroscopy to measure fluid status, aiming to detect lymphoedema earlier.
The intended place in therapy would be in diagnosing or monitoring lymphoedema related to breast cancer treatment. It could be used as an alternative to current detection or measurement techniques, such as simple tape measurement of limb circumference.
Friday, 20 January 2017
Postoperative radiotherapy for breast cancer: UK consensus statements
- Cardiac sparing
- Breast boost radiotherapy after breast-conserving surgery
- Safe omission of radiotherapy after breast-conserving surgery
- Internal mammary chain radiotherapy
- Hypofraction
- Axillary management of sentinel lymph mode-positive disease
- Partial breast radiotherapy after breast-conserving surgery
Wednesday, 18 January 2017
Refractory extrapulmonary sarcoidosis: infliximab
New Evidence Summary from NICE
According to specialists involved in this evidence summary, infliximab may be an option for some patients with severe, refractory extrapulmonary sarcoidosis (particularly cutaneous or neurological sarcoidosis); for example, those affected by disabling or disfiguring disease, or whose life expectancy is likely to be reduced.
According to specialists involved in this evidence summary, infliximab may be an option for some patients with severe, refractory extrapulmonary sarcoidosis (particularly cutaneous or neurological sarcoidosis); for example, those affected by disabling or disfiguring disease, or whose life expectancy is likely to be reduced.
Thursday, 22 December 2016
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
New NICE Technology Appraisal Guidance on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Wednesday, 16 November 2016
British Society of Breast Radiology Annual Scientific Meeting 2016
British Society of Breast Radiology Annual Scientific Meeting 2016
Axilla management of patients with pre-operatively diagnosed lymph node metastasis currently leads to overtreatment in 31.3%. There is scope to identify patients with a low nodal burden to select them for axillary staging and possibly avoid ALNC.
UHCW Research: Muthyala Sreenivas
PB.9 The use of nomograms to predict additional lymph node metastasis after Sentinel lymph node biopsy: Can they reliably identify those needing no further axillary treatment?
Overtreatment with ALNC is 75.8% in patients with sentinel node macrometastasis in 1-2 nodes. MSKCC nomogram had the best utility to identify this group with AUC 0.729. MDA2 and Helsinki nomograms also had good clinical use in deciding which patients should receive axillary clearance.
UHCW Research: Muthyala Sreenivas
PB.14 Monitoring response in breast cancer patients undergoing neoadjuvant chemotherapy - a single institution experience
Pre-treatment MRI features can serve as reliable imaging biomarkers which can be used to predict disease response to NAC. The accuracy of post-NAC MRI varies with tumour biology and imaging features, and this should be considered in decisions about surgical approach.
UHCW Research: Muthyala Sreenivas
PB.39 Outcome of assessment of patient reported symptoms during screening mammograms - Single NHS BSP unit's experience
This study shows the positive predictive value (PPV) of patients who reported symptoms turning into a breast cancer is low. Therefore, an alternate pathway of managing these patients should be investigated.
UHCW Research: Sadia Sultana, Varun Chillal and Muthyala Sreenivas
PB. 7 Potential impact of implementing new ABS guidelines for management of patients with Axillary nodal metastasis on Sentinel Lymph Node biopsy
Implementation of ABS guidelines would have resulted in 16.6% of good prognosis cancers to be undertreated whilst 71.4% of bad prognosis cancers would be over-treated with unnecessary axillary surgery and its resultant morbidity.
UHCW Research: Muthyala Sreenivas
PB.8 Outcomes of patients with Ultrasound detected lymph node metastasis: Are we over-treating the axilla?
Axilla management of patients with pre-operatively diagnosed lymph node metastasis currently leads to overtreatment in 31.3%. There is scope to identify patients with a low nodal burden to select them for axillary staging and possibly avoid ALNC.
UHCW Research: Muthyala Sreenivas
PB.9 The use of nomograms to predict additional lymph node metastasis after Sentinel lymph node biopsy: Can they reliably identify those needing no further axillary treatment?
Overtreatment with ALNC is 75.8% in patients with sentinel node macrometastasis in 1-2 nodes. MSKCC nomogram had the best utility to identify this group with AUC 0.729. MDA2 and Helsinki nomograms also had good clinical use in deciding which patients should receive axillary clearance.
UHCW Research: Muthyala Sreenivas
PB.14 Monitoring response in breast cancer patients undergoing neoadjuvant chemotherapy - a single institution experience
Pre-treatment MRI features can serve as reliable imaging biomarkers which can be used to predict disease response to NAC. The accuracy of post-NAC MRI varies with tumour biology and imaging features, and this should be considered in decisions about surgical approach.
UHCW Research: Muthyala Sreenivas
PB.39 Outcome of assessment of patient reported symptoms during screening mammograms - Single NHS BSP unit's experience
This study shows the positive predictive value (PPV) of patients who reported symptoms turning into a breast cancer is low. Therefore, an alternate pathway of managing these patients should be investigated.
UHCW Research: Sadia Sultana, Varun Chillal and Muthyala Sreenivas
Monday, 14 November 2016
Synchronous Upper and Lower Gastrointestinal Mucosa-Associated Lymphoid Tissue Lymphomas
Case Rep Gastroenterol 2016;10:241–247 (DOI:10.1159/000446576)
Mucosa-associated lymphoid tissue lymphoma (MALToma) is a subtype of B-cell non-Hodgkin’s lymphoma, comprising ∼17% of all gastrointestinal (GI) tract lymphomas. It is associated with chronic inflammation and autoimmunity, for example Helicobacter pylori gastritis and Sjogren’s syndrome, respectively. Approximately 50% of GI MALTomas occur in the stomach, with small bowel and colonic lesions being less frequent. Synchronous upper and lower GI MALTomas occur rarely, with few cases reported. We present the case of a 73-year-old patient who presented with change in bowel habit and was found to have synchronous multifocal upper and lower GI MALTomas, which did not respond to H. pylori cure or to rituximab therapy, but did respond to a combination of surgery and chemotherapy with rituximab and bendamustine.
UHCW Research: McFarlane M. · Wong J.L.H., Arasaradnam R. and Nwokolo C.
Mucosa-associated lymphoid tissue lymphoma (MALToma) is a subtype of B-cell non-Hodgkin’s lymphoma, comprising ∼17% of all gastrointestinal (GI) tract lymphomas. It is associated with chronic inflammation and autoimmunity, for example Helicobacter pylori gastritis and Sjogren’s syndrome, respectively. Approximately 50% of GI MALTomas occur in the stomach, with small bowel and colonic lesions being less frequent. Synchronous upper and lower GI MALTomas occur rarely, with few cases reported. We present the case of a 73-year-old patient who presented with change in bowel habit and was found to have synchronous multifocal upper and lower GI MALTomas, which did not respond to H. pylori cure or to rituximab therapy, but did respond to a combination of surgery and chemotherapy with rituximab and bendamustine.
Friday, 30 September 2016
Pegaspargase for treating acute lymphoblastic leukaemia
New NICE Technology Appraisal Guidance:
Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia.
Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia.
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
New Technology Appraisal Guidance from NICE:
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Wednesday, 20 July 2016
Non-Hodgkin’s lymphoma: diagnosis and management
New NICE guideline covering diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.
Subscribe to:
Posts (Atom)